Two of the world’s biggest vaccine companies, GSK and Sanofi, have joined forces in an unprecedented effort to develop a COVID-19 vaccine. GlaxoSmithKline and Sanofi, which combined have the largest vaccine manufacturing capability in the world, are working together on a high-tech vaccine, which they say could be in human trials within months
According to The Guardian, the pairing of the two companies is significant because, if successful, they have the capacity to manufacture the hundreds of millions doses likely to be required on a global scale. Paul Hudson, Chief Executive of Sanofi, said: “As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone.
Emma Walmsley, Chief Executive of GSK, said: “This collaboration brings two of the world’s largest vaccines companies together. By combining our science and our technologies, we believe we can help accelerate the global effort to develop a vaccine to protect as many people as possible from COVID-19.”
The companies plan to start phase 1 clinical trials in the second half of this year and, if successful, say the vaccine could be widely available by the second half of 2021.